Evaluation of LH, FSH, Oestradiol, Prolactin and Tumour Markers CEA and CA-125 in Sera of Iraqi Patients With Endometrial Cancer
Abstract
Background/Aim: Endometrial cancer is one of the most prevalent gynaecologic cancers in advanced nations and act as the largest proportion of tumours occurring in the uterine corpus. The aim of the study was to identify potential diagnostic biomarkers for endometrial cancer among the evaluated hormones and tumour markers to enhance early detection and improve patient outcomes.
Methods: A comparison was made between two groups of women: 30 individuals who were healthy and 30 individuals who had endometrial cancer. The participants in both groups were carefully selected to ensure that they were similar in terms of age and BMI. Luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol (E2), cancer antigen 125 (CA-125) and carcinoembryonic antigen (CEA) were analysed.
Results: As compared to healthy individuals, females diagnosed with endometrial tumour and cancer exhibited notably elevated levels of LH, FSH, E2, CA-125 and CEA. Conversely, they demonstrated significantly reduced levels of prolactin in their serum.
Conclusions: Endometrial cancer patients had significantly raised concentrations of LH, E2, FSH, PRL, CEA and CA-125 in their serum, indicating hormonal dysregulation in the development of endometrial cancer. it is not advisable to rely solely on LH, E2, FSH, PRL, CA-125 or CEA as screening markers for endometrial cancer. Instead, they should be considered as part of a comprehensive screening panel that needs to be developed in the future.
References
Sonoda Y, Barakat RR. Screening and the prevention of gynecologic cancer: endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2006 Apr;20(2):363-77. doi: 10.1016/j.bpobgyn.2005.10.015.
Oren R, Neeman M. Abstract A68: Utilizing fibroblast recruitment for detection of ovarian microtumors in the abdomen. Clin Cancer Res. 2013;19(19):A68–A68. doi: 10.1158/1078-0432.ovca13-a68.
Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, et al. Risk factors for endometrial cancer: An umbrella review of the literature. Int J Cancer. 2019 Oct 1;145(7):1719-30. doi: 10.1002/ijc.31961.
Chu W, Fyles A, Sellers M, Mccready R., Murphy J, Pal T. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis. 2007;28(2): 2139142. doi: 10.1093/carcin/bgm087.
Hsieh C H, Chang CC, Lin H, Huang EY, Huang CC, Lan KC, Chang SY. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol. 2002;86(1): 28–33. doi: 10.1006/gyno.2002.6664.
Nagamani M, Doherty MG, Smith ER, Chandrasekhar Y. Increased bioactive luteinizing hormone levels in postmenopausal women with endometrial cancer. Am J Obstet Gynecol. 1992 Dec;167(6):1825-30. doi: 10.1016/0002-9378(92)91782-6.
Tanos V, Lingwood L, Balami S. junctional zone endometrium morphological characteristics and functionality: review of the literature. Gynecol Obst Inv. 2020;85(2):107–7. doi: 10.1159/000505650.
Rodriguez AC, Blanchard Z, Maurer KA, Gertz J. Estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions. Horm Cancer. 2019;10(2): 51–63.doi: 10.1007/s12672-019-0358-9.
Che Q, Xiao X, Xu J, Liu M, Yongning LU, Liu S, Dong X. 17β-estradiol promotes endometrial cancer proliferation and invasion through IL-6 pathway. Endocr Con. 2019;8(7): 961–8. doi: 10.1530/EC-19-0258.
Karayazi Atıcı Ö, Govindrajan N, Lopetegui-González I, Shemanko CS. Prolactin: A hormone with diverse functions from mammary gland development to cancer metastasis. Semin Cell Dev Biol. 2021;114(18):159–70. doi 10.1016/j.semcdb.2020.10.005.
Yamaguchi M, Erdenebaatar C, Saito F, Honda R, Ohba T, Kyo S, et al. Prolactin enhances the proliferation of proliferative endometrial glandular cells and endometrial cancer cells. J Endocr Soc. 2020;4(2):4-7. doi: 10.1210/jendso/bvz029.
Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, et al. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol. 2007;107(1):58–65. doi: 10.1016/j.ygyno.2007.05.041.
Celik B, Bulut T, Yalcin AD. Tissue HE4 expression discriminates the ovarian serous carcinoma but not the uterine serous carcinoma patients. a new adjunct to the origin of the tumor site. Pathol Oncol Res. 2020;26(2):1145–51. doi: 10.1007/s12253-019-00675-4.
Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH. Preoperative serum CA-125 levels in treating endometrial cancer. Reprod Med. 2005 Aug;50(8):585-90. PMID: 16220763.
Kanat-Pektas M, Yenicesu O, Gungor T, Bilge U. Predictive power of sexual hormones and tumor markers in endometrial cancer. Arch Gynecol Obstet. 2010;281(4):709–15. doi: 10.1007/s00404-009-1228-4.
Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965;122(3): 467–81. doi: 10.1084/jem.122.3.467.
Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin Chem. 2001;47(4):624–30. doi: 10.1093/clinchem/47.4.624.
Bhatt AN, Mathur R, Farooque A, Verma A, Dwarakanath BS. Cancer biomarkers - Current perspectives. Ind J Med Res. 2010;132(8):129–49. PMID: 20716813.
Wang JY, Lu CY, Chu KS, Ma CJ, Wu DC, Tsai HL, Yu FJ, Hsieh JS. Prognostic significance of pre-and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res. 2007;39(4):245–50. doi: 10.1159/000101952.
Neunteufel W, Bieglmayer C, Breitenecker G. CA19-9, CA125, and CEA in endometrial carcinoma tissue and its relation to hormone receptor content and histological grading. Arch Gynecol Obstet.1988;244(1):47–52. doi: 10.1007/BF00931402.
Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW. CA 125: A useful marker in endometrial carcinoma. Am J Obstet Gynecol. 1986;155(5):1097–102. doi: 10.1016/0002-9378(86)90358-3.
Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016;93(6):468–74. PMID: 26977831.
Liu J, Xuan B, Quan Q, Gong S, Mu X. The crucial value of serum ferritin in assessing high-risk factors and prognosis for patients with endometrial carcinoma. BMC Women's Health. 2023;23(1):23-33. doi: 10.1186/s12905-023-02575-x.
Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer review of the evidence and research perspectives. Ann N Y Acad Sci. 2001 Sep;943:296-315. doi: 10.1111/j.1749-6632.2001.tb03811.x.
Charles D, Bell ET, Loraine JA, Harkness RA. Endometrial carcinoma-endocrinological and clinical studies. Am J Obstet Gynecol. 1965;91(8):1050–9. doi: 10.1016/0002-9378(65)90701-5.
Dilman VM, Golubev VN, Krylova NV. Dissociation of hormonal and antigenic activity of luteinizing hormone excreted in endometrial carcinoma patients (endogenous anahormones). Am J Obstet Gynecol. 1973;115(7):966–71. doi: 10.1016/0002-9378(73)90675-3.
Litviakova OV, Konovalov SS, Kostiuchek IN, Kleshchev MA, Kvetnoĭ IM. [Endocrine secretion in endometrial and breast malignant tumors in elderly women]. Adv Gerontol. 2009;22(1):172-5. Russian. PMID: 19827687.
Varga A, Henriksen E. Urinary excretion assays of pituitary luteinizing hormone (lh) related to endometrial carcinoma. Obstet Gynecol.1963;22(2):129–36. PMID: 14043263.
Linkov F, Yurkovetsky Z, Taioli E, Havrilesky LJ, Maxwell GL, Lokshin A. Endometrial cancer: multiplexed Luminex approaches for early detection. Expert Opin Med Diagn. 2008 May;2(5):527-37. doi: 10.1517/17530059.2.5.527.
Yildirim M, Bozkurt N, Kurdoglu M, Taskiran C, Oktem M, Dilek UK. Histopathologic findings in women with postmenopausal bleeding: Implication for endometrial thickness and circulating levels of sex steroid hormones. Arch Gynecol Obstet.2007;276(4):305–10. doi: 10.1007/s00404-007-0361-1.
Mongia SK, Rawlins ML, Owen WE, Roberts WL. Performance characteristics of seven automated CA 125 assays. Am J Clin Pathol. 2006 Jun;125(6):921-7. doi: 10.1309/NBA3-12W0-LANR-XYH9.
Helpman L, Kupets R, Covens,A, Saad RS, Khalifa MA ,Ismiil N, et al. Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. Brit J Cancer. 2014;110(3):609–15. doi: 10.1038/bjc.2013.766.
Sharma T, Nisar S, Masoodi T, Macha M, Uddin S, Akil A, et al. Current and emerging biomarkers in ovarian cancer diagnosis; CA125 and beyond. Adv Protein Chem Struct Biol. 2023;133(4):85–114. doi: 10.1016/bs.apcsb.2022.08.003.
Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85(12):1501-5. doi: 10.1080/00016340601022777.
Kim BW, Jeon YE, Cho H, Nam EJ, Kim SW, Kim S, et al. Pre-treatment diagnosis of endometrial cancer through a combination of CA125 and multiplication of neutrophil and monocyte. J Obstet Gynaecol Res. 2012 Jan;38(1):48-56. doi: 10.1111/j.1447-0756.2011.01694.x.
Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonard S, et al. A. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Brit J Cancer. 2011;104(9): 1418–25. doi: 10.1038/bjc.2011.109.
Jiang T, Huang L, Zhang S. Preoperative serum CA125: A useful marker for surgical management of endometrial cancer. BMC Cancer. 2015;15(1):44-67. doi: 10.1186/s12885-015-1260-7.
Wang M, Hui P. A timely update of immunohistochemistry and molecular classification in the diagnosis and risk assessment of endometrial carcinomas. Arch Pathol Lab Med. 2021;145(11): 1367–78. doi: 10.5858/arpa.2021-0098-RA.
Kozakiewicz B, Chądzyńska M, Dmoch-Gajzlerska E, Stefaniak M. Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI. Tumor Biol. 2016;37(7): 9367–74. doi: 10.1007/s13277-016-4784-9.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).